Journal of diabetes and its complications最新文献

{"title":"The association between age at diagnosis of diabetes and development of diabetic retinopathy and assessment of healthcare access as an effect modifier","authors":"Bria L. George ,&nbsp;Alejandro M. Perez ,&nbsp;Pura Rodriguez ,&nbsp;Prashant Parekh ,&nbsp;Noël C. Barengo","doi":"10.1016/j.jdiacomp.2024.108931","DOIUrl":"10.1016/j.jdiacomp.2024.108931","url":null,"abstract":"<div><h3>Aims</h3><div>To examine if healthcare access modifies the association between age at diagnosis of diabetes and the prevalence of retinopathy.</div></div><div><h3>Methods</h3><div>BRFSS 2020 survey data was obtained from 12,198 adults. Participants with missing information in the variables “retinopathy” (<em>N</em> = 569) and “insurance-cost barrier” (<em>N</em> = 75) were excluded. The final sample included 11,556 participants. Age at diagnosis of diabetes was the main exposure and retinopathy was the main outcome. We tested if the main association was different among the insurance-cost barrier variable. Binary logistic regression models were used to calculate odds ratios (OR) and 95 % confidence intervals (CI).</div></div><div><h3>Results</h3><div>The odds of retinopathy decreased by 22 % in patients 46–64 years-of-age (OR 0.78; 95 CI 0.6–1.0) and 57 % in those 65+ (OR 0.43; 95 CI 0.28–0.65). The odds decreased by 39 % if female (OR 0.61; 95 CI 0.48–0.77). An increase in odds by 86 % (OR 1.86; 95 CI 1.07–3.21) occurred in other non-Hispanics, 50 % (OR 1.50; 95 CI 1.13–1.99) in black non-Hispanics and 70 % (OR 1.70; 95 CI 1.17–2.46) in Hispanics. There was no evidence that age at diagnosis of diabetes and presence of retinopathy varied by insurance cost (<em>p</em> &gt; 0.05).</div></div><div><h3>Conclusion</h3><div>Health professionals may utilize these results to advocate for early disease intervention.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 2","pages":"Article 108931"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142824348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Behavioral health comorbidities in hospital outcomes post-lower extremity amputation in patients with type 1 and type 2 diabetes","authors":"Kelsey A. Schmittling","doi":"10.1016/j.jdiacomp.2025.108949","DOIUrl":"10.1016/j.jdiacomp.2025.108949","url":null,"abstract":"<div><div>Peripheral artery disease leading to chronic limb threatening ischemia (CLTI) represents a significant concern for up to 11.0 % of patients with diabetes, often culminating in amputation of the affected limb. This retrospective cohort study explores frequency of comorbid behavioral health conditions (CBHCs) in patients with diabetes and hospital stay characteristics related to post-lower extremity amputation (LEA). Utilizing patient data from the Healthcare Cost and Utilization Project from 2020, patients were categorized into groups including having comorbid depression only, alcohol abuse only, drug abuse only, more than one CBHC, or no CBHC. On average, patients with at least one CBHC underwent LEA over three years earlier (59.3<span><math><mo>±</mo></math></span>12.0 years versus 62.6<span><math><mo>±</mo></math></span>12.1 years, respectively). A greater proportion of patients with at least one CBHC were non-Hispanic White people, reside in a county metro area &lt;250,000 people, and were insured by Medicaid. Despite generally low mortality rates, patients with depression only display significantly higher survival rates relative to those without a CBHC. These findings begin exploring the socioeconomic complexities and healthcare disparities faced by patients with diabetes and behavioral health diagnoses, emphasizing the need for targeted preventive mental health screening and intervention prior to development of CLTI.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 2","pages":"Article 108949"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contents/Barcode","authors":"","doi":"10.1016/S1056-8727(25)00015-7","DOIUrl":"10.1016/S1056-8727(25)00015-7","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 2","pages":"Article 108962"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143350751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dapagliflozin has protective effects on palmitate-induced renal tubular epithelial cells by enhancing mitochondrial function and reducing oxidative stress","authors":"Tingting Ding ,&nbsp;Mingzhu Song ,&nbsp;Sihong Wang ,&nbsp;Chongbing Huang ,&nbsp;Tianrong Pan","doi":"10.1016/j.jdiacomp.2024.108930","DOIUrl":"10.1016/j.jdiacomp.2024.108930","url":null,"abstract":"<div><div>Sodium-glucose co-transporter 2 (SGLT2) inhibitors, commonly utilized for diabetic nephropathy, have demonstrated benefits beyond glucose control, including organ protection. This study investigated the protective effects of the SGLT2 inhibitor, dapagliflozin (DAPA), on palmitate-induced renal tubular epithelial cell (HK−2) injury, particularly concentrating on mitochondrial function and oxidative stress. HK-2 cells were treated with 150 μmol/L palmitate to induce mitochondrial dysfunction and oxidative stress, and they were co-treated with 2 μmol/L DAPA for 24 h. DAPA significantly increased cell viability (<em>P</em> &lt; 0.05), reduced reactive oxygen species (ROS) levels (<em>P</em> &lt; 0.001), and restored mitochondrial membrane potential (<em>P</em> &lt; 0.05). It also lowered malondialdehyde (MDA) level (<em>P</em> &lt; 0.001) and increased superoxide dismutase (SOD) expression level (<em>P</em> &lt; 0.001). Western blot analysis revealed that DAPA reversed palmitate-induced upregulation of apoptosis-related proteins, including Bax and Cytochrome C. DAPA also mitigated the overactivation of autophagy-related proteins, such as LC3 and Beclin-1, indicating its role in modulating autophagy under diabetic nephropathy. Electron microscopy confirmed improvements in mitochondrial morphology, accompanying by reduced swelling and restored cristae structure. These findings highlight the potential of DAPA, as an SGLT2 inhibitor, to mitigate renal injury by enhancing mitochondrial function and reducing oxidative stress, providing novel insights into its therapeutic value for diabetic nephropathy management.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 2","pages":"Article 108930"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142824346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uric acid in diabetic microvascular complications: Mechanisms and therapy","authors":"Xin Li,&nbsp;Bo Huang,&nbsp;Yue Liu,&nbsp;Meng Wang,&nbsp;Jing-Qiu Cui","doi":"10.1016/j.jdiacomp.2024.108929","DOIUrl":"10.1016/j.jdiacomp.2024.108929","url":null,"abstract":"<div><div>Uric acid (UA) is mainly synthesized in the liver, intestine, and vascular endothelium and excreted by the kidney (70 %) and intestine (30 %). Hyperuricemia (HUA) occurs when UA production exceeds excretion. Many studies have found that elevated UA is associated with diabetic microvascular complications (DMC), including diabetic retinopathy (DR), diabetic nephropathy (DN), and diabetic peripheral neuropathy (DPN). In addition, too high or too low UA levels will promote the occurrence and development of chronic diseases, but the relationship between UA and diabetic microvascular complications (DMC) is not clear. Therefore, the rational treatment of UA in patients with diabetes is essential. In this review, we summarize and discuss the mechanism and treatment of UA and DMC and may provide potential advice for rational drug selection.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 2","pages":"Article 108929"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of three diagnostic glycemic measures with all-cause and cardiovascular mortality in people not on antidiabetic medications: A prospective cohort study","authors":"Jiayue Zhang ,&nbsp;Wenxiao Zheng ,&nbsp;Shuting Wang ,&nbsp;Xiangyang Gao ,&nbsp;Ying Xiao ,&nbsp;Zuyao Yang","doi":"10.1016/j.jdiacomp.2025.108970","DOIUrl":"10.1016/j.jdiacomp.2025.108970","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to investigate the value of three diagnostic glycemic measures, i.e., 2-hour plasma glucose (2hPG) during 75-g oral glucose tolerance test, fasting plasma glucose (FPG), and glycated hemoglobin (HbA1c), in predicting risk of all-cause and cardiovascular mortality after adjusting for the influence of these glycemic measures on each other.</div></div><div><h3>Methods</h3><div>A total of 14,013 U.S. adults who were not on antidiabetic medications when recruited were identified from the Third National Health and Nutrition Examination Survey (NHANES III) and NHANES 2005–2016. High blood glucose was defined as 2hPG ≥11.1 mmol/L, FPG ≥7.0 mmol/L, or HbA1c ≥6.5 %, according to the American Diabetes Association 2023 standards. Two approaches were adopted to examine the value of each glycemic measure in predicting mortality risk while controlling the influence of the other two measures: (1) adjusting for 2hPG, HbA1c, and FPG in the same model, and (2) comparing individuals showing isolated elevation of 2hPG, HbA1c, or FPG with those being “normal” for all the three measures. Major non-glycemic risk factors were adjusted for in the multivariable regression analyses.</div></div><div><h3>Results</h3><div>During a median follow-up of 9.8 years, 2869 participants died, and 960 of the deaths were attributed to cardiovascular causes. When included in the model individually, elevated 2hPG, FPG, and HbA1c were all predictive of both all-cause and cardiovascular mortality (adjusted hazard ratios ranging from 1.32 to 1.55, all <em>p</em> values &lt;0.05). After controlling the influence of the other two glycemic measures, elevated 2hPG was still statistically significantly associated with the outcomes (adjusted hazard ratios ranging from 1.04 to 1.33, depending on analytical approaches), whereas elevated FPG was not, and HbA1c was associated with cardiovascular mortality only when treated as a continuous variable and when 2hPG and FPG levels were in the normal range (adjusted hazard ratio 1.27 [1.04–1.55] for 1 % increase in HbA1c).</div></div><div><h3>Conclusions</h3><div>2hPG, FPG, and HbA1c were all predictive of all-cause and cardiovascular mortality when used alone, but when combined only 2hPG retained its predictive value for both outcomes while HbA1c predicted cardiovascular mortality only when used as a continuous variable and when 2hPG and FPG were in the normal range.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 3","pages":"Article 108970"},"PeriodicalIF":2.9,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143098442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucagon-like Peptide-1 receptor agonists versus dipeptidyl-peptidase 4 inhibitors in advanced chronic kidney disease and end stage kidney disease: Real world effectiveness and persistence of therapy","authors":"F.N.U. Sidra ,&nbsp;Shubham Agarwal ,&nbsp;Paola Lockhart Pastor ,&nbsp;Donglu Xie ,&nbsp;Xilong Li ,&nbsp;Ildiko Lingvay","doi":"10.1016/j.jdiacomp.2024.108925","DOIUrl":"10.1016/j.jdiacomp.2024.108925","url":null,"abstract":"<div><h3>Background</h3><div>Atherosclerotic cardiovascular disease is the leading cause of death in people with type 2 diabetes (T2D) and chronic kidney disease (CKD) or end-stage kidney disease (ESKD). Glucagon-Like Peptide-1 receptor agonists (GLP-1RA) reduce cardiovascular events, improve glycemic control, promote weight loss, and slow progression of nephropathy. Despite these benefits and professional society treatment guidelines recommendations, GLP-1RAs remain under-utilized in people with advanced CKD and ESKD due to tolerability and safety concerns.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study comparing clinical outcomes and medication use details after initiating GLP-1RA or dipeptidyl-peptidase 4 inhibitor (DPP-4i) in people with T2D and advanced CKD or ESKD. Eligible patients were identified via electronic health record query with extraction of baseline demographics, vital signs, and laboratory values. A manual chart review was undertaken to confirm eligibility, medication use, and extract a detailed account of all side effects.</div></div><div><h3>Results</h3><div>A total of 236 eligible patients (149 in the GLP-1RA group and 87 in the DPP-4i group) were identified. The average duration of treatment was 1036 (±909.9) and 1109 (±1090.9) days for GLP-1RA and DPP-4i, respectively. The average percentage weight loss from baseline to 36 months of treatment in the GLP-1RA group was −9.6 % (95 % CI, −11.3 to −7.8) versus −2.4 % (95 % CI, −5.4 to 0.5) in the DPP-4i group (estimated treatment difference (ETD) -7.1 (95 % CI, −10.6 to −3.7) percentage-points, <em>p</em> &lt; 0.001). The change in HbA1c from baseline to 36 months of treatment was significantly greater in the GLP-1RA (−1.0 %) compared with the DPP-4i group (0.2 %) (ETD -1.2 (95 % CI, −2.1 to −0.3) percentage-points, <em>p</em> = 0.04).</div></div><div><h3>Conclusion</h3><div>In patients with T2D and advanced CKD or ESKD, treatment with GLP-1RAs in a real-world setting had long treatment persistence, and compared to DPP-4is, was associated with greater weight loss and glycemic improvement.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 1","pages":"Article 108925"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of visit-to-visit glycated hemoglobin variability on diabetes distress and its subscales","authors":"So-hyeon Hong ,&nbsp;Yongho Jee ,&nbsp;Yeon-Ah Sung ,&nbsp;Young Sun Hong ,&nbsp;Do Kyeong Song ,&nbsp;Hyein Jung ,&nbsp;Hyejin Lee","doi":"10.1016/j.jdiacomp.2024.108924","DOIUrl":"10.1016/j.jdiacomp.2024.108924","url":null,"abstract":"<div><h3>Aims</h3><div>This study aimed to investigate the correlations between glycated hemoglobin (HbA1C) variability and diabetes distress (DD) and its subscales in older patients with type 2 diabetes mellitus.</div></div><div><h3>Methods</h3><div>The cross-sectional study analyzed 175 patients with type 2 diabetes mellitus, aged ≥60 years, and underwent HbA1C testing at least three times within a 2-year. HbA1C variability was assessed using the coefficient of variation (CV), standard deviation (SD), variability independent of the mean (VIM), and variability score. DD was assessed using a diabetes distress scale (DDS) questionnaire. We analyzed four DDS subscales, including emotional burden (EB), regimen distress (RD), interpersonal distress (ID), and physician distress (PD). Significant DD was defined as a total score ≥ 34.</div></div><div><h3>Results</h3><div>All four indices of HbA1C variability were positively correlated with DDS (<em>r</em> = 0.19, <em>P</em> = 0.01 in CV; <em>r</em> = 0.19, <em>P</em> = 0.01 in SD; <em>r</em> = 0.19, <em>P</em> = 0.02 in VIM; and <em>r</em> = 0.18, <em>P</em> = 0.02 in variability score). For the DD subscales, only EB showed a significant correlation with HbA1C variability (<em>β</em> = 0.72, SE = 0.35 in CV; <em>β</em> = 0.70, SE = 0.35 in SD; <em>β</em> = 0.66, SE = 0.31 in VIM; and <em>β</em> = 0.77, SE = 0.35 in variability score).</div></div><div><h3>Conclusions</h3><div>HbA1C variability was independently linked to DD, particularly the EB subscale in older type 2 diabetes patients. This underscores the need for DD screening and intervention in patients with high HbA1C variability, irrespective of their HbA1C levels or depressive symptoms.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 1","pages":"Article 108924"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142780059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cambridge risk score, new hyperglycemia, and complications in surgical patients without diabetes","authors":"Hannah Lee ,&nbsp;Phillip J. Hartfield ,&nbsp;Abigail Thorgerson ,&nbsp;Grant P. Sinson ,&nbsp;Marjorie Wang ,&nbsp;Carlos E. Mendez","doi":"10.1016/j.jdiacomp.2024.108926","DOIUrl":"10.1016/j.jdiacomp.2024.108926","url":null,"abstract":"<div><h3>Aims</h3><div>Our study examined the association between the Cambridge Risk Score (CRS), new hyperglycemia (NH), and complications in patients undergoing elective surgery.</div></div><div><h3>Methods</h3><div>In this retrospective cross-sectional study, adult surgical patients, without diabetes, with NH (blood glucose ≥140 mg/dL) were identified, and the CRS was calculated. We used univariate regression models to evaluate the relationship between CRS and NH with 30-day readmission, length of stay (LOS), and complications. Models were stratified by surgical specialty (cardiac/vascular, general, orthopedic, neurologic).</div></div><div><h3>Results</h3><div>Of 10,531 patients in the study, 24 % had NH. After adjusting for covariates, the CRS was associated with increased odds of complications [OR 2.09; 95%CI:1.69, 2.59] and NH [OR 1.95; 95%CI:1.66, 2.29]. NH was associated with increased odds of 30-day readmission [β 1.60; 95%CI:1.31, 1.96], and increased LOS [β 0.64; 95%CI:0.59, 0.68]. When stratified by surgery type, the CRS was associated with increased LOS in neurosurgery, decreased LOS in orthopedics, and increased odds of complications and NH in neurosurgery and orthopedics.</div></div><div><h3>Conclusion</h3><div>The CRS is associated with NH, complications, and LOS in patients undergoing elective neurosurgery, orthopedic surgery, and general surgery. This suggests that CRS may have potential to help identify surgical patients at high risk for NH and complications.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 1","pages":"Article 108926"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contents/Barcode","authors":"","doi":"10.1016/S1056-8727(24)00263-0","DOIUrl":"10.1016/S1056-8727(24)00263-0","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 1","pages":"Article 108937"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143155084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}